Ways2Well Review
Best for: patients wanting required-labs structure rather than questionnaire-only intake
Ways2Well is a nationwide telehealth platform offering clinician-supervised peptide therapy and compounded GLP-1 medications including semaglutide and tirzepatide. Lab work is required as part of intake, and the clinic emphasizes a longevity and metabolic-health framing. Offers GLP-1s alongside growth-hormone secretagogue peptides and longevity protocols.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Ways2Well is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| 0.25mg | compounded | $219 |
| 1mg | compounded | $289 |
| 2.5mg | compounded | $359 |
✓ Pros
- •Required labwork enforces baseline monitoring
- •Both semaglutide and tirzepatide available
- •Clinician supervision through intake and follow-up
✗ Cons
- •Pricing higher than aggressive compounded competitors
- •3.0★ Trustpilot score lower than peers — review independent feedback before committing
Ready to start with Ways2Well?
Starting at $219/month. See current pricing and start your free consultation.
Sources & methodology
Our Ways2Well review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Ways2Well
Alan Meds
Best for: budget-conscious shoppers
Amazing Meds
Best for: patients seeking compounded retatrutide access (with eyes open about regulatory status)
AmberHealth
Best for: budget-conscious shoppers
Frequently Asked Questions
Ready to start with Ways2Well?
Starting at $219/month. See current pricing and start your free consultation.